BIS Research ( Business Intelligence and Strategy Research)

According to National Institute of Environment Health Sciences, a biomarker is an objective the measure that captures physiologic, pathologic, or anatomic characteristics of a person to understand the state of being, more precisely a warning system of the body. With the recent technological advancements in the field of mobile and digitally connected technologies, the concept of biomarkers has diverged into a new class altogether called digital biomarkers. This new emerging concept of digital biomarkers has found implications in both clinical trials as well as clinical care. The technology enables the collection of consumers generated physiological and behavioral data with the help of digitally connected tools such as wearable, implantable, and ingestible devices and sensors. The hype around wearable technology has cleared and the uptake of the same has significantly skyrocketed in the past five years. According to a report from the European Commission, the shipment of wearable

As per BIS Research analysis, the neoantigen cancer vaccine market is projected to reach $1826.1 million by 2030 from $227.1 million in 2023, at a CAGR of 34.69%. Growth in this market is expected to be driven by the ever-rising patient pool of different cancers and significant investment in research for development for cancer neoantigen vaccines to fill in the current treatment gaps. However, there are significant challenges that are restraining the market growth. These challenges include the high cost of therapy (personalized cancer vaccines), manufacturing complications, and lack of therapeutic biomarkers and assays. The market is still at the nascent phase with more than two-thirds of the neovaccines in the early stages of development. However, few neovaccines companies such as OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, and Roche have positioned themselves to launch their neovaccines in the market within the upcoming years. That being said, the neovacc